Ursodeoxycholic Acid (UDCA) Exerts Anti-Atherogenic Effects by Inhibiting RAGE Signaling in Diabetic Atherosclerosis.

A naturally occurring bile acid, ursodeoxycholic acid (UDCA), is known to alleviate endoplasmic reticulum (ER) stress at the cellular level. However, the detailed action mechanisms of UDCA in atherosclerosis are not fully understood. In this study, we demonstrated whether UDCA exerts anti-atherogeni...

Full description

Bibliographic Details
Main Authors: Jihwa Chung, Shung Hyun An, Sang Won Kang, Kihwan Kwon
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2016-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC4726772?pdf=render
_version_ 1818966433001897984
author Jihwa Chung
Shung Hyun An
Sang Won Kang
Kihwan Kwon
author_facet Jihwa Chung
Shung Hyun An
Sang Won Kang
Kihwan Kwon
author_sort Jihwa Chung
collection DOAJ
description A naturally occurring bile acid, ursodeoxycholic acid (UDCA), is known to alleviate endoplasmic reticulum (ER) stress at the cellular level. However, the detailed action mechanisms of UDCA in atherosclerosis are not fully understood. In this study, we demonstrated whether UDCA exerts anti-atherogenic activity in diabetic atherosclerosis by targeting ER stress and "receptor for advanced glycation endproduct" (RAGE) signaling. UDCA markedly reduced ER stress, RAGE expression, and pro-inflammatory responses [including NF-κB activation and reactive oxygen species (ROS) production] induced in endothelial cells (ECs) by high glucose (HG). In particular, UDCA inhibited HG-induced ROS production by increasing the Nrf2 level. In macrophages, UDCA also blocked HG-induced RAGE and pro-inflammatory cytokine expression and inhibited foam cell formation via upregulation of the ATP-binding cassette (ABC) transporters, ABCA1 and ABCG1. In the diabetic mouse model, UDCA inhibited atheromatous plaque formation by decreasing ER stress, and the levels of RAGE and adhesion molecules. In conclusion, UDCA exerts an anti-atherogenic activity in diabetic atherosclerosis by targeting both ER stress and RAGE signaling. Our work implicates UDCA as a potential therapeutic agent for prevention or treatment of diabetic atherosclerosis.
first_indexed 2024-12-20T13:32:49Z
format Article
id doaj.art-b5033fe106714fd88f8cb337c188117f
institution Directory Open Access Journal
issn 1932-6203
language English
last_indexed 2024-12-20T13:32:49Z
publishDate 2016-01-01
publisher Public Library of Science (PLoS)
record_format Article
series PLoS ONE
spelling doaj.art-b5033fe106714fd88f8cb337c188117f2022-12-21T19:39:03ZengPublic Library of Science (PLoS)PLoS ONE1932-62032016-01-01111e014783910.1371/journal.pone.0147839Ursodeoxycholic Acid (UDCA) Exerts Anti-Atherogenic Effects by Inhibiting RAGE Signaling in Diabetic Atherosclerosis.Jihwa ChungShung Hyun AnSang Won KangKihwan KwonA naturally occurring bile acid, ursodeoxycholic acid (UDCA), is known to alleviate endoplasmic reticulum (ER) stress at the cellular level. However, the detailed action mechanisms of UDCA in atherosclerosis are not fully understood. In this study, we demonstrated whether UDCA exerts anti-atherogenic activity in diabetic atherosclerosis by targeting ER stress and "receptor for advanced glycation endproduct" (RAGE) signaling. UDCA markedly reduced ER stress, RAGE expression, and pro-inflammatory responses [including NF-κB activation and reactive oxygen species (ROS) production] induced in endothelial cells (ECs) by high glucose (HG). In particular, UDCA inhibited HG-induced ROS production by increasing the Nrf2 level. In macrophages, UDCA also blocked HG-induced RAGE and pro-inflammatory cytokine expression and inhibited foam cell formation via upregulation of the ATP-binding cassette (ABC) transporters, ABCA1 and ABCG1. In the diabetic mouse model, UDCA inhibited atheromatous plaque formation by decreasing ER stress, and the levels of RAGE and adhesion molecules. In conclusion, UDCA exerts an anti-atherogenic activity in diabetic atherosclerosis by targeting both ER stress and RAGE signaling. Our work implicates UDCA as a potential therapeutic agent for prevention or treatment of diabetic atherosclerosis.http://europepmc.org/articles/PMC4726772?pdf=render
spellingShingle Jihwa Chung
Shung Hyun An
Sang Won Kang
Kihwan Kwon
Ursodeoxycholic Acid (UDCA) Exerts Anti-Atherogenic Effects by Inhibiting RAGE Signaling in Diabetic Atherosclerosis.
PLoS ONE
title Ursodeoxycholic Acid (UDCA) Exerts Anti-Atherogenic Effects by Inhibiting RAGE Signaling in Diabetic Atherosclerosis.
title_full Ursodeoxycholic Acid (UDCA) Exerts Anti-Atherogenic Effects by Inhibiting RAGE Signaling in Diabetic Atherosclerosis.
title_fullStr Ursodeoxycholic Acid (UDCA) Exerts Anti-Atherogenic Effects by Inhibiting RAGE Signaling in Diabetic Atherosclerosis.
title_full_unstemmed Ursodeoxycholic Acid (UDCA) Exerts Anti-Atherogenic Effects by Inhibiting RAGE Signaling in Diabetic Atherosclerosis.
title_short Ursodeoxycholic Acid (UDCA) Exerts Anti-Atherogenic Effects by Inhibiting RAGE Signaling in Diabetic Atherosclerosis.
title_sort ursodeoxycholic acid udca exerts anti atherogenic effects by inhibiting rage signaling in diabetic atherosclerosis
url http://europepmc.org/articles/PMC4726772?pdf=render
work_keys_str_mv AT jihwachung ursodeoxycholicacidudcaexertsantiatherogeniceffectsbyinhibitingragesignalingindiabeticatherosclerosis
AT shunghyunan ursodeoxycholicacidudcaexertsantiatherogeniceffectsbyinhibitingragesignalingindiabeticatherosclerosis
AT sangwonkang ursodeoxycholicacidudcaexertsantiatherogeniceffectsbyinhibitingragesignalingindiabeticatherosclerosis
AT kihwankwon ursodeoxycholicacidudcaexertsantiatherogeniceffectsbyinhibitingragesignalingindiabeticatherosclerosis